Editas Medicine to Seek Partner for CRISPR Eye Disease Treatment After Clinical Trial Results
According to reports from BioPharma Dive, Editas Medicine has announced that it will stop enrolling new patients in a clinical trial testing its experimental CRISPR-based gene editing treatment for a genetic form of blindness. For the inherited retinal disease (IRD) community, updates regarding early-stage clinical trials and gene-editing technologies are closely watched as researchers explore innovative approaches to addressing inherited blinding conditions.
According to the source material, Editas stated that it will no longer progress the treatment—known as EDIT-101—on its own and will search for a collaboration partner to advance the program. The decision follows weaker-than-anticipated results from a clinical trial that evaluated 14 patients. Data indicated that only three of the 14 study participants met the company's criteria for a positive response, while results for the remaining participants showed an inconsistent or negligible effect.
Despite pausing enrollment and shifting strategy away from independent development, Editas leadership noted in published statements that the trial data provide proof of concept that adeno-associated virus (AAV)-delivered CRISPR to the retina can achieve a clinically meaningful response.
As the biotech seeks a collaboration partner, the IRD community continues to monitor how developers navigate clinical findings and shape the future path of advanced ocular gene therapies. Further updates on the program's direction will depend on future partnership agreements.